www.fdanews.com/articles/122055-astrazeneca-to-pay-520-million-to-resolve-seroquel-dispute
AstraZeneca to Pay $520 Million to Resolve Seroquel Dispute
November 10, 2009
AstraZeneca has agreed to set aside $520
million as part of a deal with the U.S. attorney’s office in Philadelphia to end investigations related
to the sales and marketing practices for its antipsychotic Seroquel, the company says in its third-quarter earnings statement. Pennsylvania is one of several
states, including California and Arkansas, that have sued or investigated the company over its alleged off-label promotion of Seroquel (quetiapine fumarate)
and Seroquel XR.
Washington Drug Letter
Washington Drug Letter